Abstracts tagged "Myositis"

Abstract Number: 1206 • ACR Convergence 2025
Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Juliane Bremer¹, Judith Nagel², Jana Zschüntzsch³, Kamil K Zajt¹, Tayfun Palaz¹, Thomas Blank⁴, Aylin Ikis¹, Laura A Fischer³, Anna SM Sensmeyer³, Lara Wiechers³, Josef J Reichelt³, Kai P Hofmann⁵, Monika J Wolf⁶, Corinna Leuchtenberger⁷, Priyanka Tripathi¹, Claudia Einer⁸, Hans Zischka², Ulrike Rothermel⁷, Anna L Eck⁷, Regina Reimann⁹, Veronika Kana⁶, Elisabeth Rushing⁶, Adriano Aguzzi⁶, Marco Prinz⁴, David Liebetanz³, Francesca Odoardi³, Chao-Chung Kuo¹, Joachim Weis¹, Florian Kraft¹, Jens Schmidt¹⁰ and Mathias Heikenwälder⁷, ¹University Hospital RWTH Aachen, Aachen, Germany, ²Technical University of Munich, München, Germany, ³University Medical Center Göttingen, Göttingen, Germany, ⁴University of Freiburg, Freiburg, Germany, ⁵DKFZ Heidelberg, Göttingen, Germany, ⁶University Hospital Zürich, Zürich, Switzerland, ⁷DKFZ Heidelberg, Heidelberg, Germany, ⁸Helmholtz Munich, München, Germany, ⁹University Hospital Zürich, Zürich, Germany, ¹⁰Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disorder characterized by inflammation and degeneration with altered proteostasis. To better understand the interrelationship between these…
Abstract Number: 0866 • ACR Convergence 2025
Immunoglobulin from sera of patients with myositis can passively enter cultured human endothelial cells
Travis Kinder¹, maria Casal-Dominguez¹, Iago Pinal Fernandez², Andrew Mammen³ and Sandra Ogbonnaya-Whittlesey⁴, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³NIH, Bethesda, MD, ⁴NIH/NIAMS, Bethesda, MD
Background/Purpose: Most patients with inflammatory myopathies have autoantibodies to intracellular proteins. We previously showed that immunoglobulin colocalizes with its cognate autoantigen in muscle biopsies from…
Abstract Number: 0294 • ACR Convergence 2025
Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
Jocelyn Hui Ching Chow¹, Nikola Wilk², Ian Smith³, Ronald A. Booth⁴, Nancy Maltez², Catherine Ivory² and Jodi Warman-Chardon⁵, ¹Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ²Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ³Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ⁴Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa & Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada., Ottawa, ON, Canada, ⁵Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Department of Medicine and Cellular and Molecular Medicine, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada., Ottawa, ON, Canada
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune connective tissue diseases that often present with multisystem involvement. Autoantibodies such as myositis-specific…
Abstract Number: 2076 • ACR Convergence 2025
Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions
Latika Gupta¹, Taanya Talreja² and Peter Kerkhof³, ¹School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ²KEM Hospital, Mumbai, Maharashtra, India, ³Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Background/Purpose: The intersection of nutrition and autoimmune myopathies represents a significant yet understudied domain in rheumatological care. We conducted a meticulous analysis of online myositis…
Abstract Number: 1775 • ACR Convergence 2025
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
pradeep sosigowda¹, Phani Kumar D¹, Megha Uppin¹ and Liza rajasekhar², ¹NIMS, Hyderabad, Telangana, India, ²Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases primarily affecting skeletal muscle, with potential involvement of other organs. They are classified…
Abstract Number: 1205 • ACR Convergence 2025
Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Rachel Zeng¹, Anke Rietveld², Omar Al-Bourini¹, Rosemarie HMJM Kroon², Arno Olthoff¹, Matthias Weidenmüller¹, Per-Ole Carstens¹, Isabel Kommerell¹, Saskia G Schütz¹, Corinne GC Horlings³, Johanna G Kalf³, Bert JM de Swart³, Baziel GM van Engelen², Tim Friede¹, Sabine Hofer¹, Jens Frahm⁴, Ali Seif Amir Hosseini¹, Jens Schmidt⁵ and Christiaan GJ Saris², ¹University Medical Center Göttingen, Göttingen, Germany, ²Radboudumc Research Institute for Medical Innovation, Nijmegen, Netherlands, ³Radboudumc Research Institute for Medical Innovation, Nijmegen, Germany, ⁴Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany, ⁵Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Swallowing dysfunction -dysphagia- is a frequent and debilitating symptom in neuromuscular disorders, leading to malnutrition, cachexia, aspiration pneumonia and death. Identification of the underlying…
Abstract Number: 0864 • ACR Convergence 2025
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Danica Lee¹, Daniel Reay², Timothy Oriss², Didem Saygin³, Dana Ascherman⁴ and Daniella Schwartz⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Rush University Medical Center, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM), or myositis, comprise a group of autoimmune diseases with significant morbidity, yet the pathogenesis of myositis remains incompletely understood. In…
Abstract Number: 0293 • ACR Convergence 2025
Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis
Jackie Weiss¹, Miriam Mende², EunByul Cho³, Guo Shen³, Dmitry Karayev³, Allan L. Metzger³, Robert I. Morris³, Sabine L. Kramp², Cornelia Dähnrich² and Wolfgang Schlumberger², ¹EUROIMMUN US, Mountain Lakes, NJ, ²Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany, ³RDL Reference Laboratory Inc., Los Angeles, CA
Background/Purpose: Sporadic inclusion body myositis (sIBM) is an autoimmune disease manifesting with muscle degeneration, inflammatory infiltrates and inclusion vacuoles. Diagnosis of sIBM is hampered by…
Abstract Number: 2075 • ACR Convergence 2025
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Silvia Grazzini¹, Edoardo Conticini¹, Marco Fornaro², Chiara Rizzo³, Lidia La Barbera³, Maria Rosa Pellico⁴, Stefano Stano⁵, Florenzo Iannone⁶, Giuliana Guggino³, Nicoletta Del Papa⁴, Luca Cantarini⁷ and Bruno Frediani⁷, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ³Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁶Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Serum ferritin (FERR) is a recognized marker of immune activation and a key laboratory feature of anti-MDA5 Dermatomyositis (DM). It has been increasingly studied…
Abstract Number: 1663 • ACR Convergence 2025
Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
Wenwen Xu¹, Yiyangzi Ma², Shuang Ye³ and Qiong Fu², ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Acute exacerbation (AE) of rheumatic disease-related interstitial lung disease (RD-ILD) is a severe and potentially life-threatening condition, while there remains no clear consensus of…
Abstract Number: 1203 • ACR Convergence 2025
Rituximab in Treatment Refractory vs Treatment Naive Anti-Signal Recognition Particle (SRP) Myositis – A Case Series
israrul haque¹ and Parasar Ghosh², ¹Institute of Postgraduate Medical Education and Research(IPGMER), KOLKATA, India, ²Dept of Clinical Immunology and Rheumatology, IPGMER & SSKM HospitalGovt of West Bengal, Kolkata, India, Kolkata, West Bengal, India
Background/Purpose: Anti-Signal Recognition Particle (Anti-SRP) Myositis is a form of Polymyositis. Available consensus guidelines recommend initial combination therapy of high dose corticosteroids and Methotrexate and…
Abstract Number: 0863 • ACR Convergence 2025
Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Raphael Kirou¹, Iago Pinal-Fernandez¹, Maria Casal-Dominguez¹, Katherine Pak¹, Chiseko Ikenaga², Christopher Nelke³, Stefania Dell'orso¹, Faiza Naz¹, Shamima Islam¹, Gustavo Gutierrez-Cruz¹, Werner Stenzel⁴, Albert Selva-O'Callaghan⁵, José Milisenda⁶ and Andrew Mammen⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²The University of Tokyo, Tokyo, Japan, ³Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁴Charite University, Berlin, Germany, ⁵Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁶Hospital Clinic de Barcelona, Barcelona, Spain, ⁷NIH, Bethesda, MD
Background/Purpose: Although inclusion body myositis (IBM) is an inflammatory myopathy, there are no effective immunomodulating agents, underlying the need for better understanding of its pathogenesis.…
Abstract Number: 0292 • ACR Convergence 2025
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
Haley Zimmerman¹, Ethan Ritz², Kristin Wipfler³, Kaleb Michaud⁴ and Didem Saygin¹, ¹Rush University Medical Center, Chicago, IL, ²Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
Abstract Number: L06 • ACR Convergence 2024
Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies
Raphael Kirou¹, Iago Pinal-Fernandez¹ and Andrew Mammen², ¹NIAMS/National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD
Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
Abstract Number: L07 • ACR Convergence 2024
The Classification Criteria for Anti-Synthetase Syndrome (Class) Project
Giovanni Zanframundo¹, Sara Faghihi Kashani², Akira Yoshida³, Eduardo Dourado⁴, Iazsmin Bauer Ventura⁵, Daphne Rivero Gallegos⁶, Aravinthan Loganathan⁷, Gianluca Sambataro⁸, Francisca Bozan⁹, Sangmee Bae¹⁰, Darosa Lim¹¹, Marta Cheli¹², Yasuhiko Yamano¹³, Francesco Bonella¹⁴, Tamera Corte¹⁵, Tracy J. Doyle¹⁶, David Fiorentino¹⁷, Miguel Gonzalez-Gay¹⁸, Marie Hudson¹⁹, Masataka Kuwana²⁰, Ingrid Lundberg²¹, Andrew Mammen²², Neil McHugh²³, Frederick Miller²⁴, Carlomaurizio Montecucco¹, Chester Oddis²⁵, Jorge Rojas-Serrano⁶, Jens Schmidt²⁶, Carlo Alberto Scirè²⁷, Albert Selva-O'Callaghan²⁸, Victoria Werth¹¹, Davide Rozza²⁹, Monica Morosini³⁰, Sara Bozzini³⁰, Lorenzo Cavagna¹, Rohit Aggarwal²⁵ and the CLASS project investigators, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and University of California, San Francisco, CA, ³Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ⁴Unidade Local de Saùde da Regiao de Aveiro and Aveiro Rheumatology Research Centre, Aveiro, Portugal; Universidade de Lisboa, Lisboa, Portugal, ⁵University of Chicago, Chicago, IL, ⁶Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Mexico, ⁷Royal National Hospital for Rheumatic Diseases and University of Bath, UK; Arthritis Australia, Broadway, Glebe, NSW, Australia, ⁸University of Enna "Kore", Enna, Italy, ⁹Hospital Clinico Universidad de Chile, Santiago de Chile, Chile, ¹⁰UCLA, Los Angeles, CA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy, ¹³Tosei General Hospital, Aichi, Japan, ¹⁴University of Duisburg-Essen, Essen, Germany, ¹⁵Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷Stanford University, Redwood City, CA, ¹⁸IIS-Fundación Jiménez Díaz, Madrid, Spain, ¹⁹McGill University, Montreal, QC, Canada, ²⁰Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²¹Karolinska Institutet, Stockholm, Sweden, ²²NIH, Bethesda, MD, ²³University of Bath, Bath, United Kingdom, ²⁴NIH, NIEHS, Durham, NC, ²⁵University of Pittsburgh, Pittsburgh, PA, ²⁶University Medical Center Goettingen, Goettingen, Germany, ²⁷Univeristy of Milano Bicocca, Milan, Italy and IRCCS San Gerardo dei Tintori Foundation, Monza, Italy, ²⁸Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²⁹Italian Society for Rheumatology, Milano, Italy, ³⁰Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Italy
Background/Purpose: The aim of this study was to develop and validate new classification criteria for Anti-Synthetase Syndrome (ASSD) using data and consensus driven methodologies and…

« Previous Page
1
…
4
5
6
7
8
…
34
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].